User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 13:20, 21 October 2019 (diff | hist) . . (+11) . . Part:BBa K2933025 (→Conclusion) (current)
- 13:19, 21 October 2019 (diff | hist) . . (+43) . . Part:BBa K2933025 (→IC50 and inhibitory mechanism of inhibitors)
- 13:18, 21 October 2019 (diff | hist) . . (+11) . . Part:BBa K2933102 (→Conclusion) (current)
- 13:18, 21 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933102 (→extracorporeal IC50)
- 13:16, 21 October 2019 (diff | hist) . . (+11) . . Part:BBa K2933004 (→Conclusion) (current)
- 13:16, 21 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933004 (→extracorporeal IC50 and inhibitory mechanism of inhibitors)
- 13:15, 21 October 2019 (diff | hist) . . (+11) . . Part:BBa K2933002 (→Conclusion) (current)
- 13:14, 21 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933002 (→Extracorporeal IC50)
- 13:12, 21 October 2019 (diff | hist) . . (+11) . . Part:BBa K2933001 (→Conclusion) (current)
- 13:12, 21 October 2019 (diff | hist) . . (+110) . . Part:BBa K2933001 (→Extracorporeal IC50 and inhibitory mechanism of inhibitors)
- 13:09, 21 October 2019 (diff | hist) . . (-3) . . Part:BBa K2933001 (→Determination of the buffer condition)
- 13:07, 21 October 2019 (diff | hist) . . (-1) . . Part:BBa K2933001 (→Determination of the buffer condition)
- 13:06, 21 October 2019 (diff | hist) . . (+13) . . Part:BBa K2933001 (→Determination of the buffer condition)
- 13:04, 21 October 2019 (diff | hist) . . (-9) . . Part:BBa K2933001 (→Expression and purification)
- 13:04, 21 October 2019 (diff | hist) . . (-2) . . Part:BBa K2933001 (→Expression and purification)
- 13:03, 21 October 2019 (diff | hist) . . (+2) . . Part:BBa K2933001 (→Molecular cloning)
- 12:57, 21 October 2019 (diff | hist) . . (+3) . . Part:BBa K2933004 (→Usage and Biology)
- 12:55, 21 October 2019 (diff | hist) . . (+3) . . Part:BBa K2933001
- 12:27, 21 October 2019 (diff | hist) . . (0) . . Part:BBa K2933004
- 12:24, 21 October 2019 (diff | hist) . . (-4) . . Part:BBa K2933025 (→Effective inhibitors in vitro we founded)
- 12:24, 21 October 2019 (diff | hist) . . (+1) . . Part:BBa K2933025
- 12:22, 21 October 2019 (diff | hist) . . (+83) . . Part:BBa K2933245 (current)
- 12:20, 21 October 2019 (diff | hist) . . (+83) . . Part:BBa K2933183 (current)
- 12:14, 21 October 2019 (diff | hist) . . (+1) . . Part:BBa K2933102 (→Monitoring in living bacterial cells with antibiotics)
- 12:13, 21 October 2019 (diff | hist) . . (+135) . . Part:BBa K2933102 (→extracorporeal IC50)
- 12:10, 21 October 2019 (diff | hist) . . (+3) . . Part:BBa K2933102
- 12:04, 21 October 2019 (diff | hist) . . (+3) . . Part:BBa K2933002
- 12:03, 21 October 2019 (diff | hist) . . (0) . . Part:BBa K2933002 (→Determination of enzyme concentration)
- 11:55, 21 October 2019 (diff | hist) . . (-7) . . Part:BBa K2933001 (→Effective inhibitors in vitro we found)
- 11:50, 21 October 2019 (diff | hist) . . (-4) . . Part:BBa K2933102 (→Expression and purification)
- 11:50, 21 October 2019 (diff | hist) . . (+10) . . Part:BBa K2933102 (→Expression and purification)
- 11:47, 21 October 2019 (diff | hist) . . (+49) . . Part:BBa K2933102 (→Expression and purification)
- 11:45, 21 October 2019 (diff | hist) . . (+51) . . Part:BBa K2933002 (→Expression and purification)
- 11:29, 21 October 2019 (diff | hist) . . (+2) . . Part:BBa K2933001 (→Expression and purification)
- 16:04, 20 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933223 (→Effective inhibitors in vitro we found) (current)
- 16:03, 20 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933161 (→Effective inhibitors in vitro we found) (current)
- 16:02, 20 October 2019 (diff | hist) . . (+44) . . Part:BBa K2933101 (→Effective inhibitors in vitro we found) (current)
- 16:02, 20 October 2019 (diff | hist) . . (+45) . . Part:BBa K2933001 (→Effective inhibitors in vitro we found)
- 16:00, 20 October 2019 (diff | hist) . . (0) . . N File:Silver NDM YIZHIQVXIAN.png (current)
- 15:48, 20 October 2019 (diff | hist) . . (+50) . . Part:BBa K2933102
- 15:35, 20 October 2019 (diff | hist) . . (-5) . . Part:BBa K2933102 (→Establishment of SPG-1 inhibitor screening system)
- 15:35, 20 October 2019 (diff | hist) . . (-4) . . Part:BBa K2933102 (→Establishment of SPG-1 inhibitor screening system)
- 15:35, 20 October 2019 (diff | hist) . . (-37) . . Part:BBa K2933102 (→Establishment of SPG-1 inhibitor screening system)
- 15:35, 20 October 2019 (diff | hist) . . (+5) . . Part:BBa K2933102 (→Establishment of SPG-1 inhibitor screening system)
- 15:34, 20 October 2019 (diff | hist) . . (-3) . . Part:BBa K2933102 (→extracorporeal IC50)
- 15:33, 20 October 2019 (diff | hist) . . (+6) . . Part:BBa K2933102 (→extracorporeal IC50)
- 15:32, 20 October 2019 (diff | hist) . . (+5) . . Part:BBa K2933025 (→IC50 and inhibitory mechanism of inhibitors)
- 15:31, 20 October 2019 (diff | hist) . . (+5) . . Part:BBa K2933002 (→Extracorporeal IC50)
- 15:31, 20 October 2019 (diff | hist) . . (-5) . . Part:BBa K2933002 (→Effective inhibitors in vitro we founded)
- 15:30, 20 October 2019 (diff | hist) . . (-5) . . Part:BBa K2933102 (→Effective inhibitors in vitro we founded)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)